Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.08 USD | -1.37% | -3.95% | 0.00% |
Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 385M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.14% | 22.48B | |
-9.35% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- LENZ Stock
- News LENZ Therapeutics, Inc.
- LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials